From major journals, first or last author from the Institute for Cancer Research
Sohlberg E, Malmberg KJ(2025) The innate power of natural killer cells in cancer therapy Nat Med(in press) DOI 10.1038/s41591-025-03712-9, PubMed 40355615
Trachsel-Moncho L, Mathai BJ, Veroni C, Simonsen A(2025) SNX10 at the crossroad of endocytosis and piecemeal mitophagy Autophagy, 1-3(in press) DOI 10.1080/15548627.2025.2499641, PubMed 40327657
Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK(2025) Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50 ESMO Open, 10(5), 105073(in press) DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908
Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS(2025) Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia Clin Cancer Res, 31(10), 1943-1955 DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050
Sohlberg E, Malmberg KJ(2025) The innate power of natural killer cells in cancer therapy Nat Med(in press) DOI 10.1038/s41591-025-03712-9, PubMed 40355615
Kotkowska ZK, Haunerdinger V, Waeckerle-Men Y, Kolm-Djamei I, Duda A, Hausammann L, Schineis P, Fischer H, Sella F, Li N, Selbo PK, Høgset A, Kündig TM, Halin C, Johansen P(2025) Inflammatory cutaneous reactions with systemic CD8+ T-cell responses upon photochemical internalization of antigens in mice J Invest Dermatol(in press) DOI 10.1016/j.jid.2025.04.020, PubMed 40348329
